News
Press Releases

Curaleaf Completes Acquisition of EMMAC and Secures US$130 Million Investment from a Single Strategic Institutional Investor
WAKEFIELD, Mass., April 7, 2021 — Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer

EMMAC Life Sciences Group launches first Medical Cannabis Flower for UK Market
30 March 2021, London. EMMAC Life Sciences Group (‘EMMAC’), Europe’s largest independent cannabis company, is pleased to announce that its first range of unlicensed

Curaleaf to Enter European Cannabis Market with Acquisition of EMMAC Life Sciences Limited – Europe’s Leading Independent Cannabis Company
EMMAC Brings the Largest Vertically Integrated Independent Cannabis Company in Europe with a Presence in Key European Medical Cannabis Markets, Including the United Kingdom,

EMMAC Life Sciences Group agrees sale of wellness brands to Yooma Wellness Inc.
2 March 2021, London. EMMAC Life Sciences Group (“EMMAC” or the “Group” or the “Company”), Europe’s largest independent cannabis company, is pleased to announce

Cannabis Treatments – Mikael Sodergren, EMMAC Life Sciences & Simon Erridge, Imperial College
Researchers are just beginning to uncover the potential of medical cannabis to treat a whole host of ailments. Mikael Sodergren of EMMAC Life Sciences

Cannabis Regulations – Antonio Costanzo
No two countries are alike when it comes to developing cannabis regulations, making it difficult for companies to expand internationally. EMMAC Life Sciences CEO